BioAlliance Pharma presents preclinical and phase I clinical results with its AMEP biotherapy for metastatic melanoma
BioAlliance Pharma SA presented preclinical and promising preliminary phase I clinical results with its AMEP® biotherapy at the “Electrochemotherapy 1st International Users’ Meeting” (Bologna, Italy, November 19-20, 2010). The AMEP® biotherapy is indicated for metastatic and invasive melanoma, an advanced skin cancer refractory to most treatments. Its original mechanism of action targets specific receptors (integrins), particularly expressed by melanoma cells, both involved in tumor growth and tumor angiogenesis.
Preclinical efficacy and safety results supporting ongoing phase I clinical trial were presented. This latter trial evaluates safety and efficacy of intratumoral electrotransfer of AMEP® biotherapy in patients suffering from advanced or metastatic melanoma. It is being conducted in 3 specialized centers: in Denmark at the Copenhagen University Herlev Hospital, in France at the Gustave Roussy Institute of Villejuif and in Slovenia at the Institute of Oncology of Ljubljana.
Preliminary phase I clinical trial results showed a satisfactory safety and a well accepted electrotransfer technology in the first patients treated with the AMEP® biotherapy.
“These preliminary results confirm the interest of the anti-invasive AMEP® biotherapy in BioAlliance’s clinical programme portfolio; it represents a potential disrupting technology project”, explains Pierre Attali, COO of BioAlliance Pharma, in charge of Strategy and Medical Affairs. “This program is co-financed by OSEO's Strategic Industrial Innovation Programme to the "Cancer Anti-invasive Program" (CAP) consortium, associating the academic research, industrials and melanoma clinicians. This high quality consortium extends the scope of the program to a “companion” markers research, helpful in the follow-up of these severe patients”, adds Dominique Costantini, CEO.
Topics
Organizations
Other news from the department research and development

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents
Blood Test Provides Information on Alzheimer’s and atypical Parkinson’s
Evotec and MaRS Innovation announce first funded project under LAB150 BRIDGE

Cell-culture breakthrough: Advanced “mini brains” in the dish - Organoids that mimic human brain cortex in development and disease
Stem Cell Studies Approved for UF College of Medicine – Jacksonville - Researchers will focus on using patient’s own cells to improve health
Medtech company Theraclion obtains €8.5 million in R&D funding from OSEO
Study sheds light on treating cancer - Using light to target and kill cancer cells alternatively without surgery
Taconic Biosciences and Cellaria Biosciences collaborate to facilitate xenograft use in oncology research

Protein mingling under blue light
Global Pharmaceutical companies expect hard price competition in the rising Biosimilars segment - Bi-annual survey among more than 80 executives from globally active pharmaceutical companies based in 16 countries and spread over four continents
Centre Léon Bérard - Lyon, France
Killer silk: Making silk fibers that kill anthrax and other microbes in minutes
